<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476229</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0892</org_study_id>
    <nct_id>NCT00476229</nct_id>
  </id_info>
  <brief_title>Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies</brief_title>
  <official_title>Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      1. To determine whether the primary endpoint: the composite success rate, defined as the
      proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host
      Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have
      engrafted, is likely to be at least 40%.

      Secondary Objectives:

        1. To determine the cumulative incidence of chronic graft versus host disease.

        2. To determine the overall and disease free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of drugs used for this study will help to weaken your immune system, which
      may help to allow the donor's blood stem cells to engraft (grow) in your body.

      Anti-thymocyte globulin (also called ATG or thymoglobulin) is designed to help reduce the
      risk of transplant rejection and to help prevent graft versus host disease.

      Rituximab is designed to attach to lymphoma cells, which may cause them to die.

      If you are found to be eligible to take part in this study, you will be admitted to the
      hospital 12 days before the blood stem cell transplant (BSCT), in order to start the
      pre-transplant treatments and testing. You will have blood (about 1 tablespoon) drawn for
      routine tests every day while you are in the hospital (before and after the transplant).
      After the transplant, this blood will be used to check the status of the transplant and watch
      for any side effects.

      You will receive radiation therapy (total lymphoid irradiation) for a total of 10 days before
      the planned transplant. Radiation therapy will not be given on the weekends. The last
      radiation treatment will be on the morning of the day you receive your stem cell transplant.

      For a total of 5 days after admission to the hospital, you will also receive ATG. ATG will be
      given through a catheter (plastic tube) that is placed into the large chest vein. The
      catheter (called a central venous catheter) will stay in place throughout treatment.

      You will receive certain drugs as premedication to try to prevent an allergic reaction to the
      ATG. These may include drugs like acetaminophen (Tylenol), diphenhydramine (Benadryl), and/or
      steroids which may include solumedrol or prednisone. Tylenol is given by mouth, and Benadryl
      and steroids are given either by vein (over 10-15 minutes) or by mouth.

      The combination of ATG and radiation will weaken your immune system. A weakened immune system
      may help to allow your body to &quot;accept&quot; donor cells, and it may decrease the chance of your
      body rejecting the cells.

      If your diagnostic biopsy showed that a certain protein was found on your tumor cells, you
      may also receive rituximab therapy. If you are eligible for rituximab treatment, you will
      receive the drug once a week for 4 weeks. You will receive rituximab through the central
      venous catheter or through a vein over 6-8 hours. The first dose will be given on an
      outpatient basis at 13 days before the stem cell transplant. The next 3 doses may be given in
      the hospital or on an outpatient basis. You will receive rituximab 6 days before the
      transplant, and then 1 and 8 days after the transplant. Tylenol and steroids will be given
      before the rituximab to try to prevent an allergic reaction.

      You will be given tacrolimus to try to prevent graft versus host disease (when the donor's
      immune cells react against the recipient's body, attacking the recipient's cells and
      tissues). You will receive tacrolimus either through the central venous catheter (over 24
      hours each time) or by mouth starting 3 days before the stem cell transplant. You will
      continue receiving tacrolimus as long as your doctor feels it is necessary, which could be
      anywhere from about 3 months to several years. This will depend on factors such as whether or
      not you have graft versus host disease, how many donor cells are in your blood, and the
      status of your disease.

      Cellcept (MMF) will also be given to try to prevent graft versus host disease, starting 1 day
      after the transplant and continuing through Days 28-42 after the transplant. The MMF will be
      given twice a day through the central venous catheter over 2 hours, or by mouth.

      After the pre-transplant treatments and testing are finished, you will have the blood stem
      cell transplant. Blood stem cells from a donor will be infused over about 1 hour through your
      central venous catheter. This can be done while you are in the hospital or on an outpatient
      basis at M. D. Anderson. Steroids and Benadryl will be given through the catheter before the
      stem cell transplant to try to prevent an allergic reaction. The catheter will be removed
      once you no longer need to be given fluids, blood products, and other treatments through the
      catheter for graft versus host disease. This may take anywhere from 3 months after the
      transplant to several years.

      You will have additional blood (about 2 tablespoons) drawn, bone marrow aspirations and
      biopsies, chest CT scans, and/or chest x-rays performed as needed to check the effects of the
      transplant. You will have transfusions of blood and platelets as needed, and you will have to
      sign a separate consent document for these transfusions.

      Blood (about 1 tablespoon each time) will also be drawn at least 2-3 times a week for at
      least 100 days after the transplant, or longer if the study doctor feels it is necessary.

      Treatment will be given in the hospital or an outpatient basis at M. D. Anderson. You may
      need to stay in the hospital for 3-4 weeks. You will be taken off the study if your disease
      gets worse.

      This is an investigational study. The FDA has approved the drugs used in this study. Their
      use together in this study is investigational. Up to 40 patients will take part in this
      study. All will be enrolled at M. D. Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Success Rate</measure>
    <time_frame>Baseline to Day 100, assessment at Day 100</time_frame>
    <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>1.5 mg/kg by vein on Days -11 to -7.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Lymphoid Irradiation</intervention_name>
    <description>80 cGy daily on days -11 to -7 and -4 to 0.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>TLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Infusion</intervention_name>
    <description>PBSC infusion administered on day 0.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Blood Stem Cell Transplant</other_name>
    <other_name>BSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 by vein on days -13, -6, 1, &amp; 8. Only those patients whose tumors express CD20 will receive Rituximab.</description>
    <arm_group_label>Radiation + Chemotherapy + BSCT</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age up to 70 years.

          -  Patients with lymphoid malignancies (primary refractory or recurrent) beyond first
             remission or unresponsive to therapy and not eligible for protocols of higher
             priority. Patients should have had at least a partial remission or have stable disease
             with prior chemotherapy. Patients with bulky disease (greatest dimension &gt; 5 cm by
             radiographic or clinical examination are not eligible).

          -  Adequate renal function, as defined by serum creatinine &lt;1.8 mg/dL.

          -  Adequate hepatic function, as defined by SGPT &lt;3 times upper limit of normal; serum
             bilirubin and alkaline phosphatase &lt;3 times upper limit of normal.

          -  Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced
             vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) &gt;35% of expected
             corrected for hemoglobin. Exceptions may be allowed for patients with pulmonary
             involvement after discussing with Principal Investigator.

          -  Adequate cardiac function with left ventricular ejection fraction &gt;35%. No
             uncontrolled arrhythmias or symptomatic cardiac disease.

          -  Zubrod performance status &lt;2

          -  Patients must have an human leukocyte antigens (HLA) matched, or one A, B, C, DR, or
             DQ mismatched related or unrelated donor (by high resolution typing). Donor must be
             willing to donate peripheral blood progenitor cells.

          -  Patient should be willing to participate in the study by providing written consent.

          -  Negative beta human chorionic gonadotrophin (hCG) test in a woman of child bearing
             potential (defined as not post menopausal for 12 months or no previous surgical
             sterilization).

        Exclusion Criteria:

          -  Patients with active central nervous system (CNS) disease.

          -  Evidence of acute or chronic active hepatitis or cirrhosis.

          -  Uncontrolled infection, including Hepatitis B, C, Human immunodeficiency virus (HIV)
             or human T-cell lymphotropic virus type 1 (HTLV-1) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chitra M. Hosing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>July 13, 2011</results_first_submitted>
  <results_first_submitted_qc>July 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>Total Lymphoid Irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: July 14, 2006 to October 15, 2008. All patients were registered at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive shortness of breath</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Success Rate</title>
        <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
        <time_frame>Baseline to Day 100, assessment at Day 100</time_frame>
        <population>Analysis was per protocol. One participant was inevaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiation + Chemotherapy + BSCT</title>
            <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Success Rate</title>
          <description>Defined as the proportions of the patients who are alive at day 100, are without Grade 3-4 Graft Graft-versus-host disease (GVHD), without Grade 4 toxicity (unrelated to infection) and have engrafted. Toxicity grades according to Common Toxicity Criteria (CTC) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
          <population>Analysis was per protocol. One participant was inevaluable.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alive at 100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 year, 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Radiation + Chemotherapy + BSCT</title>
          <description>Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased bilrubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>low blood pressure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dysrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>arterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other cardiac</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pericardial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>other endocrine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <description>abdominal</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other general disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased ALT</sub_title>
                <description>Alanine aminotransferase (ALT or SGPT)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased biblrubin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>increased LDH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypermagesium</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>metabolic other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>motor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>other neruologic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>neurologic mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>skin other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to financial support.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chitra M. Hosing, MD/Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>gmccormi@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

